A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive Tumors

Inclusion Criteria: * Patients with PSMA-positive tumors including prostate cancer, breast cancer, lung cancer, and other tumor types know to express PSMA * Patients able to tolerate PET/MRI scans * Informed consent must be given and signed Exclusion Criteria: * Subjects who do not meet the above mentioned inclusion criteria * Subjects who refuse to give and/or sign the informed consent * Patients who have a history of serious adverse events related to a previous MRI or PET/CT * Patients who are unable to undergo MRI scanning due to exclusion by institutional MRI restriction policies as mentioned in the standard institutional MRI informed consent form * Patients who are currently pregnant or breast feeding. A pregnancy test within 72 hours of the first PET/MRI will be performed. * Anti-cancer treatment (chemotherapy and/or radiation therapy) within the last 2 weeks. * Renal insufficiency: elevated Creatinine and/or Glomerular Filtration Rate (GFR)\<40ml/min/1.7sqm (exclusion criterion only for contrast enhanced MRI) * Patients with a known allergy against any component of the contrast enhancing MR agent will not receive MR contrast agents. (exclusion criterion only for contrast enhanced MRI)